Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial

Increased urinary albumin excretion in diabetes not only signals nephropathy but also serves as a risk marker for cardiovascular disease. The data of MARCH (Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment) trial demonstrated that acarbose and metformin were similarly efficac...

Full description

Bibliographic Details
Main Authors:	Pan, Qingrong, Xu, Yuan, Yang, Ning, Gao, Xia, Liu, Jia, Yang, Wenying, Wang, Guang
Format:	Online
Language:	English
Published:	Wolters Kluwer Health 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998782/

id	pubmed-4998782
recordtype	oai_dc
spelling	pubmed-49987822016-08-29 Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Pan, Qingrong Xu, Yuan Yang, Ning Gao, Xia Liu, Jia Yang, Wenying Wang, Guang 4300 Increased urinary albumin excretion in diabetes not only signals nephropathy but also serves as a risk marker for cardiovascular disease. The data of MARCH (Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment) trial demonstrated that acarbose and metformin were similarly efficacious at lowering blood glucose and blood pressure, as well as improving insulin sensitivity in Chinese patients newly diagnosed with type 2 diabetes mellitus. The purpose of this study was to identify the effects of acarbose and metformin therapy on albumin excretion in MARCH study. Wolters Kluwer Health 2016-04-08 /pmc/articles/PMC4998782/ /pubmed/27057866 http://dx.doi.org/10.1097/MD.0000000000003247 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Pan, Qingrong Xu, Yuan Yang, Ning Gao, Xia Liu, Jia Yang, Wenying Wang, Guang
spellingShingle	Pan, Qingrong Xu, Yuan Yang, Ning Gao, Xia Liu, Jia Yang, Wenying Wang, Guang Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial
author_facet	Pan, Qingrong Xu, Yuan Yang, Ning Gao, Xia Liu, Jia Yang, Wenying Wang, Guang
author_sort	Pan, Qingrong
title	Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial
title_short	Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial
title_full	Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial
title_fullStr	Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial
title_full_unstemmed	Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial
title_sort	comparison of acarbose and metformin on albumin excretion in patients with newly diagnosed type 2 diabetes: a randomized controlled trial
description	Increased urinary albumin excretion in diabetes not only signals nephropathy but also serves as a risk marker for cardiovascular disease. The data of MARCH (Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment) trial demonstrated that acarbose and metformin were similarly efficacious at lowering blood glucose and blood pressure, as well as improving insulin sensitivity in Chinese patients newly diagnosed with type 2 diabetes mellitus. The purpose of this study was to identify the effects of acarbose and metformin therapy on albumin excretion in MARCH study.
publisher	Wolters Kluwer Health
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998782/
_version_	1613635558517506048

Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial

Similar Items